SCHEDULE 13G/A: Janus Henderson Group plc Discloses 4.9% Stake in 4D Molecular Therapeutics, Inc.

Janus Henderson Group plc has filed an Amendment No. 4 to Schedule 13G, reporting a beneficial ownership of 4.9% in 4D Molecular Therapeutics, Inc. as of December 31, 2024.

Summary

• Janus Henderson Group plc, a Jersey-based entity, filed an Amendment No. 4 to Schedule 13G with the SEC.
• The filing reports its beneficial ownership in 4D Molecular Therapeutics, Inc. Common Stock (CUSIP: 35104E100).
• As of December 31, 2024, Janus Henderson Group plc beneficially owns an aggregate of 2,252,240 shares of 4D Molecular Therapeutics, Inc.
• This ownership represents 4.9% of the class of securities.
• The reporting person holds these shares with shared voting power and shared dispositive power.
• The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.
• Indirect subsidiaries, including JHIUS, JHIUKL, and JHIAIFML, are registered investment advisers providing investment advice to Managed Portfolios.

Sentiment

Score: 5

Explanation: Neutral, as this is a factual regulatory filing about beneficial ownership and does not contain performance or forward-looking statements from the issuer.

Positives

• The filing indicates that Janus Henderson Group plc, a major institutional investor, maintains a significant beneficial ownership of 4.9% (2,252,240 shares) in 4D Molecular Therapeutics, Inc., suggesting continued investment interest.

Negatives

• The Schedule 13G filing, being a routine ownership disclosure, does not contain any explicit negative information regarding 4D Molecular Therapeutics, Inc.'s financial performance or operational outlook.

Future Outlook

This document is a beneficial ownership report and does not contain forward-looking statements or guidance from the issuer.

Industry Context

This filing reflects a routine disclosure by a global asset management firm, Janus Henderson Group plc, regarding its passive investment stake in 4D Molecular Therapeutics, Inc., a company operating in the biotechnology sector. Such institutional holdings are common and provide transparency into significant investor positions within the industry.

Stakeholder Impact

• Shareholders: Provides transparency regarding significant institutional ownership, which can influence market perception and liquidity.

Next Steps

• Future Schedule 13G amendments will be filed by Janus Henderson Group plc if there are significant changes in its beneficial ownership of 4D Molecular Therapeutics, Inc. (e.g., crossing 5% threshold or significant changes in holdings below 10%).

Key Dates

Keywords

4D Molecular Therapeutics, Janus Henderson Group, SEC filing, Schedule 13G, beneficial ownership, institutional investment, common stock, biotechnology, asset management